submit to the journals

Headache Journal Articles, Videos And Insights

Headache:FEATURED Articles

flipper_slider

Headache: Latest Articles

Headache: INSIGHTS

The touchNEUROLOGY website provides a selection of resources to inform clinicians and patients about the latest developments in the field. The following are quick, non peer-reviewed, opinion-based updates addressing current trends and opinion on the most recent advances in the area of neurology:

Insight
Highlights from the 17th Biennial Migraine Trust International Symposium 2018: Focus on Migraine – Value of Digital Data

Ray Ashton, Senior Medical Writer, Touch Medical Media, UK
Jon Shepheard, Neurology Account Director, Touch Medical Media, UK

Insight
Highlights from the 17th Biennial Migraine Trust International Symposium 2018: Focus on Migraine Treatment

Ray Ashton, Senior Medical Writer, Touch Medical Media, UK
Tim Sheldrick, Group Director and Advisory Editor, Touch Medical Media, UK

Insight
Recent developments in the prevention and treatment of migraine

Katrina Mountfort, Freelance Medical Writer for Touch Medical Media, UK

Headache:FEATURED VIDEOS

Editor's choice

Richard Lipton (Albert Einstein College of Medicine) discusses his recently published article, with co-authors Merle Diamond and Stewart Tepper, entitled: Expert Perspectives—Migraine Prevention for Highly Impacted Patients. In this review, they discuss the burden of migraine, barriers to the use of preventive treatments, and current and emerging approaches to treating migraine in highly impacted patients. The full article can be viewed here. Questions 1. What characteristics of a patient are highly impacted by migraine? (0:11) 2. What are the barriers that you see that keep patients from receiving benefit on current preventative therapies? (1:29) 3. What is your treatment approach for these patients and what novel therapies are on the horizon that will add to your treatment armamentarium? (3:35) Speaker disclosures: Richard B Lipton receives research support from the NIH: 2PO1 AG003949 (Program Director), 5U10 NS077308 (Pl), RO1 NS082432 (Investigator), 1 RF1 AG057531 (Site Pl), RF1 AG054548 (Investigator), 1 RO1 AG048642 (Investigator), R56 AG057548 (Investigator), K23 NS09610 (Mentor), K23AG049466 (Mentor), 1 K01AG054700 (Mentor). He also receives support from the Migraine Research Foundation and the National Headache Foundation. He serves on the editorial board of Neurology, is senior advisor to Headache, and associate editor to Cephalalgia. He has reviewed for the NIA and NINOS, holds stock options in eNeura Therapeutics and Biohaven Holdings; serves as consultant, advisory board member, or has received honoraria from: American Academy of Neurology, Alder, Allergan, American Headache Society, Amgen, Autonomic Technologies, Avanir, Biohaven, Biovision, Boston Scientific, Dr. Reddy's, Electrocore, Eli Lilly, eNeura Therapeutics, GlaxoSmithKline, Merck, Pernix, Pfizer, Supernus, Teva, Trigemina, Vector, Vedanta. He receives royalties from Wolff's Headache 7th and 8th Edition, Oxford Press University, 2009, Wiley and lnforma. Filmed at the American Academy of Neurology (AAN) Annual Meeting 2018, Los Angeles, CA, US, April 2018, with support from Alder BioPharmaceuticals.
Peter Goadsby (Professor of Neurology, Headache Group, King’s College Hospital, London, UK) discusses erenumab for the prevention of migraine, including the rationale, findings and clinical implications of the LIBERTY study. Questions 1. Could you tell us a little about erenumab and its advantages compared with current oral preventative therapies in migraine? (0:12) 2. What clinical evidence has led to the positive CHMP opinion for erenumab for the prevention of migraine? (0:44) 3. What was the rationale for the LIBERTY study? (1:24) 4. What were the efficacy and safety findings of this study? (1:50) 5. What are the implications of these findings for clinical practice? (2:40) Speaker disclosure: Peter Goadsby serves as a consultant for Amgen, Novartis, Eli Lilly, Teva Pharmaceuticals, Alder Biopharmaceuticals and Allergan. Filmed at the 4th Congress of the European Academy of Neurology (EAN), Lisbon, Portugal, June 2018.

Headache:Latest Videos

Video List based on Category on Node Page

Latest Videos

Peter Goadsby (Professor of Neurology, Headache Group, King’s College Hospital, London, UK) discusses erenumab for the prevention of migraine, including the rationale, findings and clinical implications of the LIBERTY study. Questions 1. Could you tell us a little about erenumab and its...
Patricia Pozo Rosich (Headache Unit and Headache Research Group, Vall d'Hebron University Hospital, Barcelona, Spain) talks to us about unmet needs of migraine prevention in Europe and the calcitonin gene-related peptide receptor antagonist, erenumab, in light of it recently receiving a positive...
Richard Lipton (Albert Einstein College of Medicine) discusses his recently published article, with co-authors Merle Diamond and Stewart Tepper, entitled: Expert Perspectives—Migraine Prevention for Highly Impacted Patients. In this review, they discuss the burden of migraine, barriers to the...
Prof. Peter Goadsby talks to us about premonitory-like symptomatology in migraine, the focus of his article recently published in European Neurological Review. View his article here. Speaker disclosures: nothing to disclose in relation to this video interview. Filmed at the 3rd Congress of...
Prof. Stefan Evers discusses the unmet needs and latest developments in the treatment of headache/migraine. Speaker disclosures: nothing to disclose in relation to this video interview. Filmed at the 3rd Congress of the European Academy of Neurology (EAN), Amsterdam, June 2017.
Peter Goadsby discusses the rationale for using CGRP antibodies in the treatment of migraine and the study findings so far.

LATEST TWEETS

Conference Highlights